Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (2024)

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (1) https://doi.org/10.1016/s1473-3099(19)30310-x · Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (2)

Видання: The Lancet Infectious Diseases, 2019, №9, с.1001-1012

Видавець: Elsevier BV

Автори:

  1. Kathleen M Mullane
  2. Vicki A Morrison
  3. Luis H Camacho
  4. Ann Arvin
  5. Shelly A McNeil
  6. Jessie Durrand
  7. Bernadette Campbell
  8. Shu-Chih Su
  9. Ivan S F Chan
  10. Janie Parrino
  11. Susan S Kaplan
  12. Zoran Popmihajlov
  13. Paula W Annunziato
  14. S Cerana
  15. MO Dictar
  16. P Bonvehi
  17. JP Tregnaghi
  18. L Fein
  19. D Ashley
  20. M Singh
  21. T Hayes
  22. G Playford
  23. O Morrissey
  24. J Thaler
  25. T Kuehr
  26. R Greil
  27. M Pecherstorfer
  28. L Duck
  29. K Van Eygen
  30. M Aoun
  31. B De Prijck
  32. FA Franke
  33. CHE Barrios
  34. AVA Mendes
  35. SV Serrano
  36. RF Garcia
  37. F Moore
  38. JFC Camargo
  39. LA Pires
  40. RS Alves
  41. A Radinov
  42. K Oreshkov
  43. V Minchev
  44. AI Hubenova
  45. T Koynova
  46. I Ivanov
  47. B Rabotilova
  48. V Minchev
  49. PA Petrov
  50. P Chilingirov
  51. S Karanikolov
  52. J Raynov
  53. D Grimard
  54. S McNeil
  55. D Kumar
  56. LM Larratt
  57. K Weiss
  58. R Delage
  59. FJ Diaz-Mitoma
  60. PO Cano
  61. F Couture
  62. P Carvajal
  63. A Yepes
  64. R Torres Ulloa
  65. P Fardella
  66. C Caglevic
  67. C Rojas
  68. E Orellana
  69. P Gonzalez
  70. A Acevedo
  71. KM Galvez
  72. ME Gonzalez
  73. S Franco
  74. JG Restrepo
  75. CA Rojas
  76. C Bonilla
  77. LE Florez
  78. AV Ospina
  79. R Manneh
  80. R Zorica
  81. DV Vrdoljak
  82. M Samarzija
  83. L Petruzelka
  84. J Vydra
  85. J Mayer
  86. D Cibula
  87. J Prausova
  88. G Paulson
  89. M Ontaneda
  90. K Palk
  91. A Vahlberg
  92. R Rooneem
  93. F Galtier
  94. D Postil
  95. F Lucht
  96. F Laine
  97. O Launay
  98. H Laurichesse
  99. X Duval
  100. OA Cornely
  101. B Camerer
  102. J Panse
  103. M Zaiss
  104. H-G Derigs
  105. H Menzel
  106. M Verbeek
  107. V Georgoulias
  108. D Mavroudis
  109. A Anagnostopoulos
  110. E Terpos
  111. D Cortes
  112. J Umanzor
  113. S Bejarano
  114. RW Galeano
  115. RSM Wong
  116. P Hui
  117. P Pedrazzoli
  118. L Ruggeri
  119. F Aversa
  120. A Bosi
  121. G Gentile
  122. A Rambaldi
  123. A Contu
  124. L Marei
  125. A Abbadi
  126. W Hayajneh
  127. J Kattan
  128. F Farhat
  129. G Chahine
  130. J Rutkauskiene
  131. LJ Marfil Rivera
  132. YA Lopez Chuken
  133. H Franco Villarreal
  134. J Lopez Hernandez
  135. H Blacklock
  136. RI Lopez
  137. R Alvarez
  138. AM Gomez
  139. TS Quintana
  140. MDC Moreno Larrea
  141. SJ Zorrilla
  142. E Alarcon
  143. FCA Samanez
  144. PB Caguioa
  145. BJ Tiangco
  146. EM Mora
  147. RD Betancourt-Garcia
  148. D Hallman-Navarro
  149. LJ Feliciano-Lopez
  150. HA Velez-Cortes
  151. F Cabanillas
  152. DE Ganea
  153. TE Ciuleanu
  154. DG Ghizdavescu
  155. L Miron
  156. CL Cebotaru
  157. CI Cainap
  158. R Anghel
  159. MV Dvorkin
  160. OA Gladkov
  161. NV Fadeeva
  162. AA Kuzmin
  163. ON Lipatov
  164. II Zbarskaya
  165. FS Akhmetzyanov
  166. IV Litvinov
  167. BV Afanasyev
  168. M Cherenkova
  169. D Lioznov
  170. IA Lisukov
  171. YA Smirnova
  172. S Kolomietz
  173. H Halawani
  174. YT Goh
  175. L Drgona
  176. J Chudej
  177. M Matejkova
  178. M Reckova
  179. BL Rapoport
  180. WM Szpak
  181. DR Malan
  182. N Jonas
  183. CW Jung
  184. DG Lee
  185. SS Yoon
  186. J Lopez Jimenez
  187. I Duran Martinez
  188. JF Rodriguez Moreno
  189. C Solano Vercet
  190. R de la Camara
  191. M Batlle Massana
  192. S-P Yeh
  193. C-Y Chen
  194. H-H Chou
  195. C-M Tsai
  196. C-H Chiu
  197. N Siritanaratkul
  198. L Norasetthada
  199. V Sriuranpong
  200. K Seetalarom
  201. H Akan
  202. F Dane
  203. MA Ozcan
  204. GH Ozsan
  205. SF Kalayoglu Besisik
  206. A Cagatay
  207. S Yalcin
  208. A Peniket
  209. SR Mullan
  210. KM Dakhil
  211. K Sivarajan
  212. JJ-G Suh
  213. A Sehgal
  214. F Marquez
  215. EG Gomez
  216. MR Mullane
  217. WL Skinner
  218. RJ Behrens
  219. DR Trevarthe
  220. MA Mazurczak
  221. EA Lambiase
  222. CA Vidal
  223. SY Anac
  224. GA Rodrigues
  225. B Baltz
  226. R Boccia
  227. MS Wertheim
  228. CS Holladay
  229. D Zenk
  230. W Fusselman
  231. JL Wade III
  232. AJ Jaslowsk
  233. J Keegan
  234. MO Robinson
  235. RS Go
  236. J Farnen
  237. B Amin
  238. D Jurgens
  239. GF Risi
  240. PG Beatty
  241. T Naqvi
  242. S Parshad
  243. VL Hansen
  244. M Ahmed
  245. PD Steen
  246. S Badarinath
  247. A Dekker
  248. MA Scouros
  249. DE Young
  250. W Graydon Harker
  251. SD Kendall
  252. ML Citron
  253. S Chedid
  254. JG Posada
  255. MK Gupta
  256. S Rafiyath
  257. J Buechler-Price
  258. S Sreenivasappa
  259. CH Chay
  260. JM Burke
  261. SE Young
  262. A Mahmood
  263. JW Kugler
  264. G Gerstner
  265. J Fuloria
  266. ND Belman
  267. R Geller
  268. J Nieva
  269. BP Whittenberger
  270. BMY Wong
  271. TP Cescon
  272. G Abesada-Terk
  273. MJ Guarino
  274. A Zweibach
  275. EN Ibrahim
  276. G Takahashi
  277. MA Garrison
  278. RB Mowat
  279. BS Choi
  280. IA Oliff
  281. J Singh
  282. KA Guter
  283. K Ayrons
  284. KM Rowland
  285. SJ Noga
  286. SB Rao
  287. A Columbie
  288. MT Nualart
  289. GR Cecchi
  290. LT Campos
  291. M Mohebtash
  292. MR Flores
  293. R Rothstein-Rubin
  294. BM O'Connor
  295. G Soori
  296. M Knapp
  297. FG Miranda
  298. BW Goodgame
  299. M Kassem
  300. R Belani
  301. S Sharma
  302. T Ortiz
  303. HL Sonneborn
  304. AB Markowitz
  305. D Wilbur
  306. E Meiri
  307. VS Koo
  308. HS Jhangiani
  309. L Wong
  310. S Sanani
  311. SJ Lawrence
  312. CM Jones
  313. C Murray
  314. C Papageorgiou
  315. JS Gurtler
  316. JL Ascensao
  317. K Seetalarom
  318. ML Venigalla
  319. M D'Andrea
  320. C De Las Casas
  321. DJ Haile
  322. FU Qazi
  323. JL Santander
  324. MR Thomas
  325. VP Rao
  326. M Craig
  327. RJ Garg
  328. R Robles
  329. RM Lyons
  330. RK Stegemoller
  331. S Goel
  332. S Garg
  333. P Lowry
  334. C Lynch
  335. B Lash
  336. T Repka
  337. J Baker
  338. BS Goueli
  339. TC Campbell
  340. DA Van Echo
  341. YJ Lee
  342. EA Reyes
  343. FM Senecal
  344. G Donnelly
  345. P Byeff
  346. R Weiss
  347. T Reid
  348. E Roeland
  349. A Goel
  350. DM Prow
  351. DS Brandt
  352. HG Kaplan
  353. JE Payne
  354. MG Boeckh
  355. PJ Rosen
  356. RR Mena
  357. R Khan
  358. RF Betts
  359. SA Sharp
  360. VA Morrison
  361. D Fitz-Patrick
  362. J Congdon
  363. N Erickson
  364. R Abbasi
  365. S Henderson
  366. A Mehdi
  367. EJ Wos
  368. E Rehmus
  369. L Beltzer
  370. RA Tamayo
  371. T Mahmood
  372. AC Reboli
  373. A Moore
  374. JM Brown
  375. J Cruz
  376. DP Quick
  377. JL Potz
  378. KW Kotz
  379. M Hutchins
  380. NM Chowhan
  381. YD Devabhaktuni
  382. P Braly
  383. RA Berenguer
  384. SC Shambaugh
  385. TJ O'Rourke
  386. WA Conkright
  387. CF Winkler
  388. FEK Addo
  389. JP Duic
  390. KP High
  391. ME Kutner
  392. R Collins
  393. DR Carrizosa
  394. DJ Perry
  395. E Kailath
  396. N Rosen
  397. R Sotolongo
  398. S Shoham
  399. T Chen

Список літератури

  1. Habel, The epidemiology of herpes zoster in patients with newly diagnosed cancer, Cancer Epidemiol Biomarkers Prev, № 22, с. 82
    Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (3) https://doi.org/10.1158/1055-9965.EPI-12-0815
  2. Johnson, Annual incidence rates of herpes zoster among an immunocompetent population in the United States, BMC Infect Dis, № 15, с. 502
    Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (4) https://doi.org/10.1186/s12879-015-1262-8
  3. Mao, Healthcare utilization and costs among patients with herpes zoster and solid tumor malignancy on chemotherapy: a retrospective cohort study, Medicine, № 96
    Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (5) https://doi.org/10.1097/MD.0000000000008746
  4. Yenikomshian, The epidemiology of herpes zoster and its complications in Medicare cancer patients, BMC Infect Dis, № 15, с. 106
    Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (6) https://doi.org/10.1186/s12879-015-0810-6
  5. Ansaldi, Real-world effectiveness and safety of a live-attenuated herpes zoster vaccine: a comprehensive review, Adv Ther, № 33, с. 1094
    Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (7) https://doi.org/10.1007/s12325-016-0355-0
  6. Dworkin, Recommendations for the management of herpes zoster, Clin Infect Dis, № 44, с. S1
    Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (8) https://doi.org/10.1086/510206
  7. Gnann, Varicella-zoster virus: atypical presentations and unusual complications, J Infect Dis, № 186, с. S91
    Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (9) https://doi.org/10.1086/342963
  8. Lewis, Atypical disseminated herpes zoster: management guidelines in immunocompromised patients, Cutis, № 100, с. 321
  9. Cohen, Herpes zoster, N Engl J Med, № 369, с. 1766
    Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (10) https://doi.org/10.1056/NEJMcp1302674
  10. Oxman, A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults, N Engl J Med, № 352, с. 2271
    Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (11) https://doi.org/10.1056/NEJMoa051016
  11. Schmader, Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years, Clin Infect Dis, № 54, с. 922
    Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (12) https://doi.org/10.1093/cid/cir970
  12. Cunningham, Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older, N Engl J Med, № 375, с. 1019
    Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (13) https://doi.org/10.1056/NEJMoa1603800
  13. Lal, Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults, N Engl J Med, № 372, с. 2087
    Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (14) https://doi.org/10.1056/NEJMoa1501184
  14. Oostvogels, Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults with hematologic malignancies: a phase III, randomized clinical trial, Open Forum Infect Dis, № 4, с. S415
    Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (15) https://doi.org/10.1093/ofid/ofx163.1040
  15. Vink, Immunogenicity and safety of a candidate subunit adjuvanted herpes zoster vaccine in adults with solid tumors vaccinated before or during immunosuppressive chemotherapy treatment: a phase II/III, randomized clinical trial, Open Forum Infect Dis, № 4, с. S417
  16. Hata, Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants, N Engl J Med, № 347, с. 26
    Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (16) https://doi.org/10.1056/NEJMoa013441
  17. Redman, Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine, J Infect Dis, № 176, с. 578
    Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (17) https://doi.org/10.1086/514077
  18. Mullane, Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults, J Infect Dis, № 208, с. 1375
    Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (18) https://doi.org/10.1093/infdis/jit344
  19. Eberhardson, Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with autoimmune disease: a phase 2, randomized, double-blind, placebo-controlled clinical trial, Clin Infect Dis, № 65, с. 1174
    Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (19) https://doi.org/10.1093/cid/cix484
  20. Parrino, Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies, Vaccine, № 35, с. 1764
    Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (20) https://doi.org/10.1016/j.vaccine.2016.10.055
  21. Winston, Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial, Lancet, № 391, с. 2116
    Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (21) https://doi.org/10.1016/S0140-6736(18)30631-7
  22. Smith, Development and validation of a γ interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus, Clin Diagn Lab Immunol, № 8, с. 871
    Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (22) https://doi.org/10.1128/CDLI.8.5.871-879.2001
  23. Keller, Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies, J Virol Methods, № 14, с. 177
    Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (23) https://doi.org/10.1016/0166-0934(86)90048-0
  24. Cleeland, Assessment of pain in cancer: measurement issues
  25. Clopper, The use of confidence on fiducial limits illustrated in the case of the binomial, Biometrika, № 26, с. 404
    Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (24) https://doi.org/10.1093/biomet/26.4.404

Публікації, які цитують цю публікацію

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

Annika Fendler, Elisabeth G. E. de Vries, Corine H. GeurtsvanKessel, John B. Haanen, Bernhard Wörmann, Samra Turajlic, Marie von Lilienfeld-Toal

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (25) https://doi.org/10.1038/s41571-022-00610-8

2022, Nature Reviews Clinical Oncology, №6, с.385-401

Scopus

WoS

Цитувань Crossref:4

Cutaneous Findings in Hematologic Malignancies: Part 2

Sabrina Popatia, Karolyn A. Wanat

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (26) https://doi.org/10.1182/hem.v19.3.2022317

2022, The Hematologist, №3

Цитувань Crossref:0

COVID-19 vaccination in cancer patients: Immune responses one year after the third dose

Roberta Campagna, Federica Dominelli, Maria Antonella Zingaropoli, Fabio Ciurluini, Giorgia Grilli, Alessandra Amoroso, Angelo De Domenico, Donatella Amatore, Maria Stella Lia, Enrico Cortesi, Vincenzo Picone, Claudio Maria Mastroianni, Maria Rosa Ciardi, Riccardo De Santis, Florigio Lista, Guido Antonelli, Ombretta Turriziani

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (27) https://doi.org/10.1016/j.vaccine.2024.03.017 · Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (28)

2024, Vaccine, №10, с.2687-2694

Scopus

WoS

Цитувань Crossref:0

Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem

Zrinka Sertić, Marko Lucijanić, Sandra Bašić-Kinda, Ranka Serventi Seiwerth, Vlatka Periša, Dubravka Sertić, Božena Coha, Dražen Pulanić, Zinaida Perić, Lana Desnica, Mirta Mikulić, Marijo Vodanović, Ivo Radman-Livaja, Dragana Šegulja, Dunja Rogić, Toni Valković, Igor Aurer, Nadira Duraković

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (29) https://doi.org/10.3390/biomedicines10112892 · Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (30)

2022, Biomedicines, №11, с.2892

Scopus

WoS

Цитувань Crossref:5

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

Alemnew F Dagnew, Osman Ilhan, Won-Sik Lee, Dariusz Woszczyk, Jae-Yong Kwak, Stella Bowco*ck, Sang Kyun Sohn, Gabriela Rodriguez Macías, Tzeon-Jye Chiou, Dimas Quiel, Mickael Aoun, Maria Belen Navarro Matilla, Javier de la Serna, Samuel Milliken, John Murphy, Shelly A McNeil, Bruno Salaun, Emmanuel Di Paolo, Laura Campora, Marta López-Fauqued, Mohamed El Idrissi, Anne Schuind, Thomas C Heineman, Peter Van den Steen, Lidia Oostvogels, Kadir Acar, Boris Afanasyev, Aránzazu Alonso Alonso, Veli-Jukka Anttila, Pere Barba Suñol, Norbert Blesing, Terrance Comeau, Teresa del Campo, Patricia Disperati, Richard Eek, HyeonSeok Eom, Gianluca Gaidano, Sebastian Grosicki, Thierry Guillaume, Wojciech Homenda, William Hwang, Nikolay Ilyin, Anna Johnston, Seok Jin Kim, Ching-Yuan Kuo, Aleksey Kuvshinov, Dong-Gun Lee, Jae Hoon Lee, Je-Jung Lee, Stephane Lepretre, Albert Kwok-Wai Lie, Alessandro Lucchesi, Ahmed Masood, Naheed Mir, Anna Carolina Miranda Castillo, Kathleen Mullane, Alexandr Myasnikov, Raquel Oña Navarrete, Karlis Pauksens, Andrew Peniket, Jaime Perez de Oteyza, David Pohlreich, Humphrey Pullon, Philippe Quittet, Philippe Rodon, Lars Rombo, Olga Samoylova, Johan Sanmartin Berglund, Ariah Schattner, Dominik Selleslag, Marjatta Sinisalo, Faisal Sultan, Koen Theunissen, Paul Turner, Po-Nan Wang, Lucrecia Yáñez San Segundo, Jo-Anne Young, Pierre Zachee, Francesco Zaja

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (31) https://doi.org/10.1016/s1473-3099(19)30163-x · Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (32)

2019, The Lancet Infectious Diseases, №9, с.988-1000

Scopus

WoS

Цитувань Crossref:82

Vaccines

Andrew W. Ambler, Francina D. Towne, Benjamin D. Brooks

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (33) https://doi.org/10.1016/bs.seda.2021.07.002

2021, Side Effects of Drugs Annual, с.355-374

Scopus

Цитувань Crossref:0

Effectiveness of Live Attenuated Varicella-Zoster Vaccine in Adults Older than 50 Years in Japan: A Retrospective Cohort Study

Kazuhiro Matsumoto, Satoko Ohfuji, Kana Inohara, Masateru Akechi, Hiroko Kumashiro, Motoki Ishibashi, Shin Irie, Yoshio Hirota

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (34) https://doi.org/10.3390/vaccines11020259 · Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (35)

2023, Vaccines, №2, с.259

Scopus

WoS

Цитувань Crossref:0

Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients With Solid or Hematologic Cancer

Michael J Boeckh, Ann M Arvin, Kathleen M Mullane, Luis H Camacho, Drew J Winston, Vicki A Morrison, Kimberly Hurtado, Jessie Durrand Hall, Lei Pang, Shu-Chih Su, Susan S Kaplan, Paula W Annunziato, Zoran Popmihajlov, V212 Protocol 001 Trial Group and V212 Protocol 011 Trial Group

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (36) https://doi.org/10.1093/ofid/ofaa172 · Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (37)

2020, Open Forum Infectious Diseases, №7

Scopus

WoS

Цитувань Crossref:0

Casting a wider protective net: Anti-infective vaccine strategies for patients with hematologic malignancy and blood and marrow transplantation

Malgorzata McMasters, Barbra M. Blair, Hillard M. Lazarus, Carolyn D. Alonso

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (38) https://doi.org/10.1016/j.blre.2020.100779 · Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (39)

2021, Blood Reviews, с.100779

Scopus

WoS

Цитувань Crossref:2

A Review of Vaccinations in Adult Patients with Secondary Immunodeficiency

Elda Righi, Tolinda Gallo, Anna Maria Azzini, Fulvia Mazzaferri, Maddalena Cordioli, Mara Merighi, Evelina Tacconelli

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (40) https://doi.org/10.1007/s40121-021-00404-y · Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (41)

2021, Infectious Diseases and Therapy, №2, с.637-661

Scopus

WoS

Цитувань Crossref:11

Знайти всі цитування публікації

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a tw… (2024)

FAQs

Is varicella vaccine safe for immunocompromised patients? ›

Varicella vaccine is recommended for vaccinating people in specific groups who do not have evidence of immunity against varicella, including: People with HIV infection. People with some degree of immunodeficiency.

Is the shingles vaccine safe for immunocompromised? ›

At a glance. ACIP recommends 2 doses of recombinant zoster vaccine (RZV, Shingrix) for the prevention of shingles and related complications in adults aged ≥19 years who are or will be immunodeficient or immunosuppressed because of disease or therapy.

How is varicella zoster treated in immunocompromised patients? ›

Adults with herpes zoster can be treated with oral acyclovir at a dose of 800 mg five times daily. The recommended dose of intravenous acyclovir for VZV infections is 10 mg/kg every 8 hours, although higher doses (12–15 mg/kg) are sometimes used for life-threatening infections, especially in immunocompromised patients.

What is the safety and efficacy of the shingles vaccine? ›

Shingles can cause a painful rash and have dangerous complications, particularly if it spreads to the eyes. Shingrix is given in 2 doses given about 6 months apart. The study found 2 doses were 76% effective against shingles, while 1 dose was 64% effective.

Which type of vaccine should be avoided in immunocompromised patients? ›

MMR vaccines

MMR -containing vaccines are contraindicated in people who are significantly immunocompromised as a result of a medical condition. MMR -containing vaccines are contraindicated in people receiving high-dose systemic immunosuppressive therapy, such as chemotherapy, radiation therapy or oral corticosteroids.

What is the concern with giving inactivated vaccines to patients who are immunocompromised? ›

Non-live vaccines, including inactivated and recombinant, may generally be administered to immunocompromised people if indicated because the antigens in the vaccine cannot replicate and there is no increase in the risk of vaccine-associated adverse events; however, the magnitude and duration of vaccine-induced immunity ...

Does the CDC recommend Shingrix vaccine for immunocompromised? ›

Adults 19 years and older who have weakened immune systems because of disease or therapy should also get two doses of Shingrix, as they have a higher risk of getting shingles and related complications.

Is Shingrix safe for autoimmune patients? ›

1 Shingrix is effective and safe for most people, including people with autoimmune disorders. The CDC currently recommends that people with chronic medical conditions, such as RA, get the shingles vaccine.

Which groups of 70 age patients should not receive zoster vaccine? ›

As with other live viral vaccines, zoster vaccine is generally contraindicated in people who are immunocompromised due to disease or medication. Haematologic malignancy and metastatic cancer are absolute contraindications.

What are the complications of shingles in immunocompromised patients? ›

Given the importance of a well-functioning, integrated immune system in maintaining a state of lifelong viral latency, it is logical that patients who are immunocompromised are at increased risk of developing HZ, having a more severe episode, and having complications such as postherpetic neuralgia and a range of ...

Is shingles contagious to immunosuppressed people? ›

Shingles is not contagious; however, the potential for exposing a person to another viral infection that leads to shingles is very real. The answer to the question of whether or not shingles (herpes zoster) is contagious is quite succinct and emphatic.

What is the most appropriate medication for use in treating varicella-zoster infection in an immunocompromised child? ›

Intravenous acyclovir is recommended only for the treatment of varicella in immunocompromised children or in healthy children with varicella pneumonia or encephalitis. In some instances, acyclovir may be considered for teenagers and adults with otherwise uncomplicated varicella.

Why was the zoster vaccine discontinued? ›

One side effect of Zostavax that cannot be ignored is the potential to cause death, which is why it was ultimately discontinued. Other side effects it can cause are blindness, chickenpox, nerve damage, and paralysis.

How protected are you after the first shingles vaccine? ›

The shingles vaccine is 97% effective in preventing shingles in people ages 50 to 69 years old. It's 91% effective in people ages 70 years and older. In addition, the shingles vaccine is 91% effective in preventing PHN in people ages 50 to 69 years old.

What is the long term effectiveness of the live zoster vaccine in preventing shingles a cohort study? ›

Among people who received the vaccine, incidence of shingles was reduced by 67% (95% confidence interval 65% to 69%) during the first year after vaccination. Thereafter, vaccine effectiveness waned substantially to 15% (5% to 24%) after 10 years.

Who should not get the varicella vaccine? ›

In people with serious immune system problems, this vaccine may cause an infection that may be life-threatening. People with serious immune system problems should not get varicella vaccine.

What is the best vaccine for immunocompromised people? ›

CDC recommends the 2023–2024 updated COVID-19 vaccines—Pfizer-BioNTech or Moderna—to protect against serious illness from COVID-19. Everyone aged 6 months and older who is moderately or severely immunocompromised needs at least 1 dose of a 2023-2024 updated COVID-19 vaccine.

Who is contraindicated to the varicella-zoster vaccine? ›

Patients can not receive the vaccine if they present with febrile illness or have active, untreated tuberculosis. Vaccination is contraindicated in pregnant females, and women should delay pregnancy for three months after vaccination by using effective birth control.

Should immunocompromised avoid chickenpox? ›

Immunocompromised people with chickenpox are at increased risk of developing complications (such as pneumonia, encephalitis, hepatitis, and disseminated intravascular coagulopathy) [CDC, 2021].

Top Articles
The Famous 100 Cookie Recipe | Condensed Milk Cookies
Crispy Air Fryer Bacon Recipe - Evolving Table
Tears Of The Fallen Moon Bdo
Td Share The Green Referral Credit
Busted Newspaper Birmingham Al
Who is on the FBI Most Wanted list cryptocurrency?
Mark Johnson Weather Salary
Osage actor talks Scorsese, 'Big Uncle Energy' and 'Killers of the Flower Moon'
Strawwberrymilkkk
Uhsbhlearn.com
Gt7 Roadster Shop Rampage Engine Swap
Great Clips Coupons → 20% Off | Sep 2024
Making a Docker Container Use a VPN – Natural Born Coder
35Mmx45Mm In Inches
Vector Driver Setup
How To Customise Mii QR Codes in Tomodachi Life?
Banette Gen 3 Learnset
Troy Bilt Belt Diagram
Meg 2: The Trench Showtimes Near Phoenix Theatres Laurel Park
Hannah Nichole Kast Twitter
Craigslist Gaming Chair
Tethrd Coupon Code The Hunting Public
Kfc $30 Fill Up Substitute Sides
Ups Access Point Location Georgetown Photos
Caldwell Idaho Craigslist
Master Series Snap On Tool Box
The Legend of Zelda: Every Reincarnation of Princess Zelda Explained
Frostbite Blaster
Craigslist Caldwell Id
Roundpoint Mortgage Mortgagee Clause
Cars & Trucks By Owner
Generac Find My Manual
Courtney Callaway Matthew Boynton
Craigslist Mexico Cancun
Bdo Passion Of Valtarra
Leccion 4 Lesson Test
9294027542
Adventhealth Employee Handbook 2022
Honeywell V8043E1012 Wiring Diagram
Get Over It Stables
Kcu Sdn
Www.manhunt.cim
How to Watch Age-Restricted YouTube Videos Without Signing In
Entegra Forum
Naviance Hpisd
Aces Fmc Charting
Minute Clinic Schedule 360
Gasmonkeygarage.com Cars For Sale
Ultipro Fleet Farm
Wyoming Roads Cameras
Select Costco Stores: Insta360 X3 5.7K 360° Action Camera Adventure Bundle $100 (In-Store Purchase Only)
Nfl Espn Expert Picks 2023
Latest Posts
Article information

Author: Greg O'Connell

Last Updated:

Views: 6073

Rating: 4.1 / 5 (62 voted)

Reviews: 85% of readers found this page helpful

Author information

Name: Greg O'Connell

Birthday: 1992-01-10

Address: Suite 517 2436 Jefferey Pass, Shanitaside, UT 27519

Phone: +2614651609714

Job: Education Developer

Hobby: Cooking, Gambling, Pottery, Shooting, Baseball, Singing, Snowboarding

Introduction: My name is Greg O'Connell, I am a delightful, colorful, talented, kind, lively, modern, tender person who loves writing and wants to share my knowledge and understanding with you.